REDWOOD CITY, Calif., April 16, 2007 /PRNewswire-FirstCall/ -- Threshold Pharmaceuticals, Inc. , today announced multiple presentations regarding its oncology pipeline, which includes two preclinical presentations on the Hypoxically Activated Prodrug, TH-302, and two research presentations from Threshold's Tubulin Inhibitor program. The presentations will take place at the 2007 American Association for Cancer Research (AACR) annual meeting being held April 14 - 18, 2007, at the Los Angeles Convention Center in Los Angeles, CA.
The following presentations will take place on Tuesday, April 17, 2007 from 8:00am to 12:00pm:
Poster 3988: In Vivo Anti-Cancer Efficacy of a Hypoxia Activated Prodrug, TH-302 Poster Session: Angiogenesis Inhibitors Poster 3985: Anti-Tumor Activity of a Hypoxia Activated Prodrug, TH-302, in Pancreatic and Prostate Orthotopic Models of Cancer Poster Session: Angiogenesis Inhibitors Poster 3984: A Novel Class of Tubulin Inhibitors that Exhibit Potent Antiproliferation and Vascular Targeting Activities Poster Session: Angiogenesis Inhibitors Poster 3965: 3-Aroylindazoles: Their Synthesis and Potential Use for Cancer Treatment Poster Session: Drug Discovery Design 1
Copies of the posters will be available on the Threshold website on Tuesday, April 17, 2007 at http://investor.thresholdpharm.com/calendar.cfm.
About Threshold Pharmaceuticals
Threshold is a biotechnology company focused on the discovery and development of small molecule therapeutics for the potential treatment of cancer. By selectively targeting abnormally-proliferating tumor cells, the Company's drug candidates are designed to be potentially more effective and less toxic to healthy tissues than conventional treatments. For additional inf ormation, please visit our website (www.thresholdpharm.com).
Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding Threshold's product candidates, and potential therapeutic uses and benefits of our product candidates. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward- looking statements. Potential risks and uncertainties include, but are not limited to, Threshold's ability to commence its anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Annual Report on Form 10-K, which was filed with the Securities Exchange Commission on March 15, 2007 and is available from the SEC's website (www.sec.gov) and on our website (www.thresholdpharm.com) under the heading "Investors." We do not intend to update any forward-looking statement made in this news release.
Contact: Denise T. Powell Sr. Director, Corporate Communications Threshold Pharmaceuticals, Inc. firstname.lastname@example.org
CONTACT: Denise T. Powell, Sr. Director, Corporate Communications ofThreshold Pharmaceuticals, Inc., +1-650-474-8206, email@example.com
Web site: http://www.thresholdpharm.com/
Ticker Symbol: (NASDAQ-NMS:THLD)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company